Integrated Biopharma, Inc. INBP
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -63.20% | -9.84% | -719.51% | 169.10% | -129.13% |
| Total Depreciation and Amortization | 5.06% | 7.55% | 1.22% | 0.00% | 7.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 485.06% | -110.96% | -160.83% | -85.95% | 231.01% |
| Change in Net Operating Assets | -169.01% | 2.77% | 53.35% | 277.43% | 26.03% |
| Cash from Operations | -330.95% | -16.21% | -52.57% | 120.14% | -4.06% |
| Capital Expenditure | -- | 100.00% | 86.13% | -1,830.00% | 108.62% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,583.33% | 125.00% | 86.13% | -4,225.00% | 96.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.09% | 0.00% | 0.00% | -1,000.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -9.09% | 0.00% | 0.00% | -116.42% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -364.65% | -12.03% | -47.90% | 70.80% | 30.80% |